Kesimpta (Ofatumumab)

Ofatumumab targets the CD20 protein on B‑lymphocytes. By binding to CD20, it activates complement and cellular immune mechanisms that destroy these B cells, reducing their contribution to the autoimmune inflammation that drives multiple sclerosis activity.

The dosing regimen for Kesimpta is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. Healthcare professionals follow the approved label and adjust the schedule as needed for individual patients.

Safety data for ofatumumab in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a specialist.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling—and necessary import documentation.

Kesimpta is a fully human anti‑CD20 monoclonal antibody administered subcutaneously, offering a convenient at‑home dosing schedule. Compared with intravenous anti‑CD20 agents, it reduces infusion‑related reactions and clinic visits, while providing comparable efficacy in reducing relapses.

Kesimpta must be stored refrigerated between 2 °C and 8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain stability and potency.

Kesimpta is given as a subcutaneous injection. After an initial loading phase, patients typically self‑administer the medication at home using a pre‑filled syringe or autoinjector, following the training and schedule provided by their healthcare professional.

Serious risks include severe infections such as opportunistic or bacterial infections, reactivation of hepatitis B, progressive multifocal leukoencephalopathy (PML), and severe hypersensitivity reactions including anaphylaxis. Patients should be monitored closely for signs of infection or immune‑related complications.

Kesimpta is contraindicated in individuals with known hypersensitivity to ofatumumab or any of its excipients. It should also be avoided in patients with active severe infections or those who cannot receive required vaccinations before therapy initiation.